Clinical trials: Patients With Advanced Solid Tumors
Malignancies, Solid Malignant Tumor
JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
This is a Phase I, multicenter, single-arm, open-label clinical study designed to evaluate the safety and tolerability of JL19001 Injection as monotherapy (Phase Ia) or in combination with standard therapy (Phase Ib) in patients…
- Conditions
- Malignancies, Solid Malignant Tumor, NHL (Non-Hodgkin Lymphoma), Solid Tumor Cancer
- Trial name
- NCT07603479
- Testing
- JL19001, subcutaneous injection, 1 μg/kg, JL19001, subcutaneous injection, 5 μg/kg, JL19001, subcutaneous injection,10 μg/kg
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
Neoplasms
A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors
The purpose of this exploratory study is to investigate the safety and determine the maximum tolerated dose (MTD) of TAS-114 in combination with capecitabine in patients with advanced solid tumors for which the patients have no…
- Trial name
- NCT02025803
- Testing
- TAS-114/capecitabine
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Taiho Oncology, Inc.
Tumor, Solid, Cancer, Metastatic
Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors
This phase I trial is designed to efficiently identify the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) for the combination therapy regimen of the IDO1 inhibitor SHR9146 when administered in combination with…
- Conditions
- Tumor, Solid, Cancer, Metastatic, Neoplasm Malignant
- Trial name
- NCT03491631
- Testing
- SHR9146+SHR-1210, SHR9146+SHR-1210+Apatinib
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Neoplasms, Carcinoma, Hepatocellular
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
This is the first in human trial clinical study of AST-201 in patients with GPC3-positive advanced solid tumors. This study aims to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of…
- Conditions
- Neoplasms, Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms
- Trial name
- NCT06687941
- Testing
- AST-201
- Where
- 4 sites in South Korea
- Volunteers
- 70 people
- Sponsor
- Aptamer Sciences, Inc.
Patients With Advanced Solid Tumors
BAT7104 in Patients With Advanced Solid Tumours
This is a prospective multi-centre, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT7104 in Patients with Advanced Solid Tumours in Australia.
- Trial name
- NCT05200013
- Testing
- BAT7104
- Where
- 2 sites in Australia
- Volunteers
- 14 people
- Sponsor
- Bio-Thera Solutions
Advanced Solid Tumors, Neoplasms
A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors
The purpose of the study is to determine safety and tolerability of CVX-045 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Neoplasms, Carcinoma, Cancer
- Trial name
- CVX-045-101 (NCT00879554)
- Testing
- CVX-045
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Pfizer
Solid Tumor, NSCLC
D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer
A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of D-0316 in Patients with Locally Advanced/Metastatic Non Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor…
- Conditions
- Solid Tumor, NSCLC, EGFR T790M
- Trial name
- NCT03861156
- Testing
- D-0316
- Where
- China
- Volunteers
- 290 people
- Sponsor
- InventisBio Co., Ltd
Solid Tumor
Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors
This is a multicenter, open-label, dose-escalation study to assess the safety, tolerability and Pharmacokinetics of MGFR1877S.
- Trial name
- NCT01363024
- Testing
- MFGR1877S
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
Locally Advanced Solid Tumor
Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors
The purpose of this study is to establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of OBI-999 as monotherapy, and to characterize the safety and preliminary clinical activity profile of the RP2D of…
- Trial name
- NCT04084366
- Testing
- OBI-999
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- OBI Pharma, Inc
Advanced Cancer, Refractory Cancer
A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients
The Epidermal Growth Factor Receptor (EGFR) is a validated target for the treatment of cancer, and agents targeting EGFR such as erlotinib (Tarceva®) are approved by the FDA for treatment of various solid tumors.
- Trial name
- NCT00551850
- Testing
- AV-412
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers
A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors
This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics (PK) of oral (PO) GDC-0941 administered in combination with PO erlotinib in patients with advanced solid…
- Trial name
- NCT00975182
- Testing
- GDC-0941, erlotinib HCl
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 58 people
- Sponsor
- Genentech, Inc.
Advanced Cancer, Advanced Solid Tumor
A Study in Patients With Advanced Cancers
A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
- Trial name
- NCT05320588
- Testing
- BIO-106, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 332 people
- Sponsor
- BiOneCure Therapeutics Inc.
Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [225Ac]Ac-ETN029 and the safety and imaging properties of [111In]In-ETN029 in patients aged ≥ 18 years with locally advanced…
- Conditions
- Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
- Trial name
- NCT07006727
- Testing
- 225Ac-ETN029, 111In-ETN029
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor, Adult
A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of fully human anti-VEGFR2 monoclonal antibody, HLX06, in patients with advanced or metastatic tumors refractory to…
- Trial name
- NCT03494231
- Testing
- HLX06
- Where
- Taiwan
- Volunteers
- 5 people
- Sponsor
- Henlix, Inc
Advanced Solid Tumor
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated…
- Trial name
- NCT04890613
- Testing
- CX-5461
- Where
- 8 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- Senhwa Biosciences, Inc.
Solid Tumors, Lymphomas
Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas
The purpose of this trial is to explore the clinical utility of two investigational antibodies in patients with advanced cancer or lymphomas. This is a multi-center, open-label Phase I/Ib study.
- Trial name
- NCT02740270
- Testing
- GWN323, PDR001
- Where
- 9 sites in United States, Canada and 4 more
- Volunteers
- 92 people
- Sponsor
- Novartis Pharmaceuticals
RAS Mutation, Advanced Solid Tumor
A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations
The purpose of this study is to test if the BG-85738 is safe and if it works in patients with advanced solid tumors with RAS mutations when it is given on its own and in combination.
- Conditions
- RAS Mutation, Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT07746141
- Testing
- BG-85738, Tislelizumab, Cetuximab
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 100 people
- Sponsor
- BeOne Medicines
Advanced Solid Tumors, Pancreatic Cancer
Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours
This study is an open label, two-part, First in Human (FIH) Phase 1/2 dose-finding study designed to determine the safety, tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and proof-of-concept (POC) of OMO-103 in…
- Conditions
- Advanced Solid Tumors, Pancreatic Cancer, CRC
- Trial name
- MYCure (NCT04808362)
- Testing
- OMO-103
- Where
- 3 sites in Spain
- Volunteers
- 22 people
- Sponsor
- Peptomyc S.L.
Advanced Solid Tumors, HER2-positive Breast Cancer
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors
This will be a Phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in participants with HER2-positive advanced solid tumors with or without…
- Trial name
- NCT05593094
- Testing
- ZN-A-1041, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b
- Where
- 36 sites in United States, Australia and 5 more
- Volunteers
- 210 people
- Sponsor
- Hoffmann-La Roche
Advanced Cancer
Phase 1/2 Study of UI-102 in Selected Advanced Cancers
This phase 1/2 first-in-human study is designed to assess the safety and efficacy of UI-102, a TLR7/8 agonist encapsulated in a Cholesteryl Pullulan Nanoparticle.
- Trial name
- NCT07605962
- Testing
- UI-102
- Where
- 3 sites in United States
- Volunteers
- 140 people
- Sponsor
- United Immunity, co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.